Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL910613 | 0.82 | CA1 (0.46) | — | |
| SCHEMBL28923763 | 0.78 | — | — | |
| SCHEMBL6450709 | 0.78 | CYP1A2 (0.38) | — | |
| SCHEMBL8789060 | 0.77 | PEPD (0.38) | ALDH1A1 | |
| SCHEMBL910836 | 0.77 | KDM4E (0.36) | — | |
| SCHEMBL7314132 | 0.76 | — | — | |
| SCHEMBL98027 | 0.75 | — | — | |
| SCHEMBL29203936 | 0.73 | ADH1B (0.37) | ALDH1A1 | |
| SCHEMBL2439565 | 0.73 | ADH1B (0.37) | ALDH1A1 | |
| SCHEMBL26243 | 0.73 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 94 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9416084-B2 | Method of producing ingenol-3-angelate | LEO LABORATORIES LIMITED (IE) | 2016-08-16 | — | — | US | claimed |
| EP-1670809-B1 | SYNTHESIS AND MANUFACTURE OF PENTOSTATIN AND ITS PRECURSORS, ANALOGS AND DERIVATIVES | MAYNE PHARMA PLC (GB) | 2016-01-13 | — | — | EP | claimed |
| JP-4830128-B2 | — | — | 2011-12-07 | — | — | JP | claimed |
| EP-1670809-A2 | SYNTHESIS AND MANUFACTURE OF PENTOSTATIN AND ITS PRECURSORS, ANALOGS AND DERIVATIVES | SuperGen, Inc. (US) | 2006-06-21 | — | — | EP | claimed |
| US-20050267056-A1 | Synthesis and manufacture of pentostatin and its precursors, analogs and derivatives | MAYNE PHARMA (USA) INC. | 2005-12-01 | — | — | US | claimed |
| WO-2005027838-A2 | SYNTHESIS AND MANUFACTURE OF PENTOSTATIN AND ITS PRECURSORS, ANALOGS AND DERIVATIVES | SUPERGEN, INC. (US) | 2005-03-31 | — | — | WO | claimed |
| US-12006311-B2 | Compounds for use in preventing or treating cancer | FUNDACIÓ HOSPITAL UNIVERSITARI VALL D'HEBRONINSTITUT DE RECERCA (ES) | 2024-06-11 | — | — | US | disclosed |
| CN-117986153-A | Ionizable cationic lipid compound, and preparation method and application thereof | 晟迪生物医药(苏州)有限公司 | 2024-05-07 | — | — | CN | disclosed |
| WO-2024083861-A1 | 1-(SULFONYL)-N-PHENYLPYRROLIDINE-2-CARBOXAMIDES DERIVATIVES AND USE THEREOF | SELABTEC SCIENCES, SLU (ES) | 2024-04-25 | — | — | WO | disclosed |
| EP-4356909-A1 | 1-(SULFONYL)-N-PHENYLPYRROLIDINE-2-CARBOXAMIDES DERIVATIVES AND USE THEREOF | Selabtec Sciences, SLU (ES) | 2024-04-24 | — | — | EP | disclosed |
| CN-111032671-B | Protected tetraose, method for the production thereof and use thereof as a substrate for transglucosidase receptors in the chemoenzymatic synthesis of shigella flexneri-specific oligosaccharides | 巴斯德研究所 | 2024-01-12 | — | — | CN | disclosed |
| US-20240002423-A1 | PROTECTED TETRASACCHARIDES, THEIR PROCESS OF PREPARATION AND THEIR USE AS TRANSGLUCOSYLASE ACCEPTOR SUBSTRATES IN THE CHEMO-ENZYMATIC SYNTHESIS OF SHIGELLA FLEXNERI SPECIFIC OLIGOSACCHARIDES | PASTEUR INSTITUT (FR) | 2024-01-04 | — | — | US | disclosed |
| US-11834468-B2 | Protected tetrasaccharides, their process of preparation and their use as transglucosylase acceptor substrates in the chemo-enzymatic synthesis of Shigella flexneri specific oligosaccharides | INSTITUT PASTEUR (FR) | 2023-12-05 | — | — | US | disclosed |
| WO-2005027838-A2 | SYNTHESIS AND MANUFACTURE OF PENTOSTATIN AND ITS PRECURSORS, ANALOGS AND DERIVATIVES | SUPERGEN, INC. (US) | 2005-03-31 | — | — | WO | disclosed |
| EP-1409500-A1 | ALKYLATED INOSITOLGLYCANS AND THEIR USES | Rodaris Pharmaceuticals Limited (GB) | 2004-04-21 | — | — | EP | disclosed |
| EP-1406913-A2 | INOSITOLGLYCANS AND THEIR USES | Rodaris Pharmaceuticals Limited (GB) | 2004-04-14 | — | — | EP | disclosed |
| US-20010053767-A1 | Compounds and their uses | RODARIS PHARMACEUTICALS LIMITED (GB) | 2001-12-20 | — | — | US | disclosed |
| US-20010051606-A1 | Compounds and their uses | RADEMACHER GROUP LIMITED (GB) | 2001-12-13 | — | — | US | disclosed |
| WO-2001085747-A1 | ALKYLATED INOSITOLGLYCANS AND THEIR USE | RODARIS PHARMACEUTICALS LIMITED (GB) | 2001-11-15 | — | — | WO | disclosed |
| WO-2001085740-A2 | INOSITOLGLYCANS AND THEIR USES | RODARIS PHARMACEUTICALS LIMITED (GB) | 2001-11-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11834468-B2 | Protected tetrasaccharides, their process of preparation and their use as transglucosylase acceptor substrates in the chemo-enzymatic synthesis of Shigella flexneri specific oligosaccharides | SI, GALE, FUT5 | ALDH1A1 1374/4885 |
| US-12006311-B2 | Compounds for use in preventing or treating cancer | UGT1A3, UGT1A1, UGT1A6 | ALDH1A1 14/4885 |
| US-20050267056-A1 | Synthesis and manufacture of pentostatin and its precursors, analogs and derivatives | UMPS, THPO, DHPS | ALDH1A1 2644/4885 |
| US-20240002423-A1 | PROTECTED TETRASACCHARIDES, THEIR PROCESS OF PREPARATION AND THEIR USE AS TRANSGLUCOSYLASE ACCEPTOR SUBSTRATES IN THE CHEMO-ENZYMATIC SYNTHESIS OF SHIGELLA FLEXNERI SPECIFIC OLIGOSACCHARIDES | SI, GALE, FUT5 | ALDH1A1 1374/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.